August 11, 2020 -- Romark has initiated a phase III clinical trial of its investigational new drug candidate Nt-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
The drug aims to reduce the sustained response, as well as reduce the rate of progression to severe COVID-19, according to Romark.
The randomized, double-blind trial will study a maximum of 800 people who are 12 and older and have fevers and respiratory symptoms consistent with COVID-19. These participants will be given either Nt-300 or a placebo twice daily for five days. Efficacy analyses will examine those participants who have laboratory-confirmed SARS-CoV-2 infection.
Romark anticipates sharing results near the end of 2020.